Vital Transformation quantified how the Inflation Reduction Act’s pricing rules may be suppressing late-stage small-molecule oncology follow-on development. The research, published Oct. 20, linked the IRA to a 37% decline in follow-on small-molecule oncology studies and a 27% decline in lead-indication approvals, along with a smaller reduction in orphan oncology studies. The analysis examined 1,148 secondary clinical trials tied to 364 FDA-approved medicines across 175 companies from 2018 to 2025, comparing activity before and after the IRA introduction. The report argues the “pill penalty” reduces incentives for additional indications because follow-on studies don’t reset CMS pricing protection. For biotech and pharma, the headline is clear: changes in reimbursement policy can reverberate into pipeline breadth and the economics of indication expansion—particularly in oncology where multi-indication strategies are common.